Essentials of Informed Consent to Psychedelic Medicine

JAMA Psychiatry, Journal Year: 2024, Volume and Issue: 81(6), P. 611 - 611

Published: April 10, 2024

Interest in administering psychedelic agents as mental health treatment is growing rapidly. As drugmakers invest developing medicines for several psychiatric indications, lawmakers are enacting legal reforms to speed access globally, and agencies preparing approve these treatments. Meanwhile, US states, such Oregon Colorado, making psychedelics available supervised use outside the conventional care system.

Language: Английский

---

Psychedelics for the Treatment of Psychiatric Disorders: Interpreting and Translating Available Evidence and Guidance for Future Research

American Journal of Psychiatry, Journal Year: 2025, Volume and Issue: 182(1), P. 21 - 32

Published: Jan. 1, 2025

During the past decade, there has been extraordinary public, media, and medical research interest in psychedelics as promising therapeutics for difficult-to-treat psychiatric disorders. Short-term controlled trial data suggest that certain are effective safe treatment of major depressive disorder, treatment-resistant depression, posttraumatic stress disorder. Preliminary evidence also supports efficacy other disorders (e.g., tobacco alcohol use disorders). Notwithstanding promise psychedelics, concerns have arisen with respect to interpretability translatability study results. For example, aspects related short- long-term safety, abuse liability, essentiality psychedelic "trip" psychological support are, inter alia, insufficiently characterized agents. The overarching aims this overview 1) review methodological affect inferences interpretation extant studies disorders, 2) provide guidance future development psychiatry, critical clinical implementation.

Language: Английский

---

The Therapeutic Potential of Psychedelics in Treating Substance Use Disorders: A Review of Clinical Trials

Medicina, Journal Year: 2025, Volume and Issue: 61(2), P. 278 - 278

Published: Feb. 6, 2025

Background and Objectives: Substance use disorders (SUDs) affect millions worldwide. Despite increasing drug use, treatment options remain limited. Psychedelic-assisted therapy (PAT), integrating psychedelic substances with psychotherapy, offers a promising alternative by addressing underlying neural mechanisms. Materials Methods: This review's purpose is to investigate the current understanding of for treating SUDs, including tobacco, alcohol, addiction. The systematic review approach focused on clinical trials randomized controlled conducted from 2013 2023. search was performed using PubMed, Google Scholar, Consensus AI, following PRISMA guidelines. Studies involving psychedelics like LSD, psilocybin, ibogaine, ayahuasca various addictions were included, excluding naturalistic studies reviews. Results: Our results highlight key findings 16 investigating SUDs. Psychedelics psilocybin showed promise in reducing alcohol tobacco dependence, being particularly effective decreasing cravings promoting long-term abstinence. revealed significant improvements substance reduction, especially when combined psychotherapy. However, variability dosages study design calls more standardized approaches. These emphasize potential SUD treatment, though further large-scale research needed validate these develop consistent protocols. Conclusions: reviewed past decade's international experience, emphasizing growing SUDs pertaining cocaine dependence. such as ketamine can reduce promote psychological well-being, regulatory barriers specialized training are necessary integrate therapies into mainstream addiction safely. offer those unresponsive conventional methods.

Language: Английский

---

Psychedelics in the Treatment of Substance Use Disorders and Addictive Behaviors: A Scoping Review

Current Addiction Reports, Journal Year: 2025, Volume and Issue: 12(1)

Published: Feb. 8, 2025

Language: Английский

---

Spirituality as a Therapeutic Approach for Severe Mental Illness: Insights from Neural Networks

Religions, Journal Year: 2024, Volume and Issue: 15(4), P. 489 - 489

Published: April 16, 2024

This article explores the link between spirituality/religiosity and mental health from a clinical neuroscience perspective, taking into account advancements in neuroimaging. Specifically, it examines how spirituality influences treatment of illness, emphasizing importance neuronal networks cognitive emotional processes, with focus on default mode network (DMN) brain. The discussion role managing disorders alterations DMN may provide insight impact health. By also discussing spiritual non-spiritual meditation, as well experiences facilitated by use psychedelics psychiatry associated brain networks, we aim to elaborate limitations within psychiatry.

Language: Английский

---

Novel medications for problematic alcohol use

Journal of Clinical Investigation, Journal Year: 2024, Volume and Issue: 134(11)

Published: June 2, 2024

Alcohol-related harm, a major cause of disease burden globally, affects people along spectrum use. When harmful pattern drinking is present in the absence significant behavioral pathology, low-intensity brief interventions that provide information about health consequences continued use large benefits. At other end spectrum, profound including despite knowledge potentially fatal consequences, warrants medical diagnosis, and treatment strongly indicated. Available pharmacological treatments are supported by scientific evidence but vastly underutilized. Discovery additional medications, with favorable balance efficacy versus safety tolerability can improve clinical uptake treatment, allow personalized outcomes. Here, we delineate conditions when pharmacotherapy should be considered relation to main diagnostic systems discuss endpoints represent meaningful We then review specific developments three categories targets show promise for expanding toolkit. GPCRs remain largest category successful drug across contemporary medicine, several GPCR currently pursued alcohol-related indications. Endocrine another established category, promising have emerged alcohol Finally, immune modulators revolutionized multiple conditions, they may also hold potential produce benefits patients problems.

Language: Английский

---

The potential of 5‐methoxy‐N,N‐dimethyltryptamine in the treatment of alcohol use disorder: A first look at therapeutic mechanisms of action

Addiction Biology, Journal Year: 2024, Volume and Issue: 29(4)

Published: April 1, 2024

Abstract Alcohol use disorder (AUD) remains one of the most prevalent psychiatric disorders worldwide with high economic costs. Current treatment options show modest efficacy and relapse rates are high. Furthermore, there increases in gap few new medications have been approved past 20 years. Recently, psychedelic‐assisted therapy psilocybin lysergic acid diethylamide has garnered significant attention AUD. Yet, they require amounts therapist input due to prolonged subjective effects (~4–12 h) leading costs impeding implementation. Accordingly, is an increasing interest rapid short‐acting psychedelic 5‐methoxy‐ N,N ‐dimethyltryptamine (5‐MeO‐DMT). This paper offers a first look at potential therapeutic mechanisms for AUD by reviewing current literature on 5‐MeO‐DMT. Primarily, 5‐MeO‐DMT able induce mystical experiences ego‐dissolution together psychological flexibility mindfulness. could decrease symptoms through alleviation mood‐related comorbidities consistent negative reinforcement self‐medication paradigms. In addition, preliminary evidence indicates that modulates neural oscillations might subserve (increases gamma ), mindfulness theta reorganization executive control networks coherence across frequencies) improve emotion regulation inhibition. Finally, animal studies characterized neuroplasticity, anti‐inflammation, 5‐HT 2A receptor agonism, downregulation metabotropic glutamate 5 clinical implications comorbidities. The concludes several recommendations future research establish purported action.

Language: Английский

---

Self‐reported experiences and perspectives on using psychedelics to manage opioid use among participants of two Reddit communities

Addiction, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 16, 2025

The opioid crisis continues to exert a tremendous toll in North America, with existing interventions often falling short of addressing ongoing needs. Psychedelics are emerging as possible alternative therapy for mental health and substance use disorders. This study aimed gather insights on how people or considering using psychedelics manage disorder (OUD), these experiences perceived impact what lessons imply future research practice. We conducted qualitative the Reddit online community platform. extracted posts that contained key psychedelic terms from two most subscribed-to subreddits dedicated discussions OUD treatment (r/OpiatesRecovery r/Methadone) 2018 2021. thematically analyzed content 151 relevant their respective comments. Two prominent themes identified were perspectives effectiveness treating OUD, mechanisms through which thought desire opioids. For many, deemed have strong via multiple mechanisms, including alleviating physical symptoms dependence, shifting motivations around opioids underlying problems reasons use. Others saw potential promise exaggerated, acknowledging many eventually return use, even considered dangerous. There appear be diverse effects treat an urgent need controlled studies better understand different they may used context treatments strategies must combined ensure safety effectiveness. Integrating who drugs will help guide toward effective person-centered enhance wellness.

Language: Английский

---

Effects of psychedelics on opioid use disorder: a scoping review of preclinical studies

Cellular and Molecular Life Sciences, Journal Year: 2025, Volume and Issue: 82(1)

Published: Jan. 21, 2025

The current opioid crisis has had an unprecedented public health impact. Approved medications for use disorder (OUD) exist, yet their limitations indicate a need innovative treatments. Limited preliminary clinical studies suggest specific psychedelics might aid OUD treatment, though most evidence remains observational, with few controlled trials. This review aims to bridge the gap between preclinical findings and potential applications, following PRISMA-ScR guidelines. Searches included MEDLINE, Embase, Scopus, Web of Science, focusing on in vivo involving opioids animals, excluding pain those lacking control groups. Forty met criteria, covering both classic non-classic psychedelics. Most showed that 18-methoxycoronaridine (18-MC), ibogaine, noribogaine, ketamine could reduce self-administration, alleviate withdrawal symptoms, change conditioned place preference. However, seven (two 2,5-dimethoxy-4-methylamphetamine (DOM), three one 18-MC, ketamine) no improvement over controls. A methodological quality assessment rated as having unclear quality. Interestingly, are limited iboga derivatives, which were effective, but these agents may have higher cardiovascular risk than other under-explored date. strengthens support translational testing targets OUD. It also suggests include broader range beyond derivatives can explore several ongoing questions field, such mechanism action behind therapeutic effect, safety profiles, doses, frequency administrations needed.

Language: Английский

---

Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

Addiction, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 30, 2025

Abstract Background and aims This is the first systematic review of extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco (TUD) other substance disorders (SUD). We aimed to summarise evidence efficacy AUD, TUD, SUD; evaluate its quality; offer recommendations research. Methods was a prospectively registered narrative open‐label, randomised controlled trials (RCT), observational studies d‐lysergic acid diethylamide (LSD), mescaline, psilocybin, ayahuasca, ketamine, ibogaine 3,4‐methylenedioxymethamphetamine (MDMA). Eligible had SUD outcome measures including craving, use, relapse, remission. Study quality evaluated using Cochrane Collaboration Risk Bias (RoB), RoB in Non‐randomised Studies Interventions tool. Certainty RCTs judged Grading Recommendations, Assessment, Development, Evaluations (GRADE) Findings 37 (2035 participants) were reviewed: LSD (14; n = 1047); mescaline (1; 7); psilocybin (4; 135); ayahuasca (3; 101); ketamine (10; 579); (5; 166); MDMA 14). There no serious adverse events reported any study. A two‐centre, placebo‐controlled, phase 2 superiority RCT double‐blind, four‐arm, placebo‐controlled AUD yielded best efficacy. Progression support 3 secured from an open‐label study TUD nine cannabis disorder, cocaine opioid (all with high‐RoB low‐GRADE certainty). Conclusions Psilocybin‐assisted appears have among treatments alcohol, tobacco, disorders. Future research should report safety events; screen person‐level characteristics indicating that contraindicated; strive mitigate blinding participants interventions; factorial designs drug psychotherapy trials; build consensus field‐specific Core Outcome Set.

Language: Английский

---